From GlobeNewswire: 2025-05-28 19:43:00

Neurocrine Biosciences, Inc. presented positive data from the Phase 2 study of NBI-1117568 for adults with schizophrenia at the ASCP 2025 Annual Meeting. Nxera Pharma is a biopharma company in Japan developing specialty medicines with an agile business model and an extensive pipeline of over 30 active programs. The company employs around 400 people in key locations globally and is listed on the Tokyo Stock Exchange. For more information, visit www.nxera.life or contact Nxera’s Media and Investor Relations team. Please note that forward-looking statements in this press release may be subject to various risks.



Read more at GlobeNewswire: Nxera Pharma Notes Neurocrine Biosciences Presents New